Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBrGlobeNewsWire • 01/21/21
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial OfficerGlobeNewsWire • 12/17/20
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary DiseaseGlobeNewsWire • 12/10/20
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020GlobeNewsWire • 11/30/20
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)Insider Monkey • 10/26/20
Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract InfectionsGlobeNewsWire • 09/24/20
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute PyelonephritisGlobeNewsWire • 09/08/20
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/08/20
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/07/20
Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business UpdateGlobeNewsWire • 08/06/20
Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/30/20
Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020GlobeNewsWire • 07/29/20
Spero Therapeutics (SPRO) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/01/20
Spero Therapeutics, Inc. (SPRO) Shares March Higher, Can It Continue?Zacks Investment Research • 05/12/20